Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation
NCT00002787
Completed
The purpose of this trial is to test the safety and immune response to four immunizations with this vaccine made from a protein produced by the patient's tumor. There is no guarantee or promise that this procedure will be successful
Gender:
ALL
Ages:
All
Trial Updated:
05/02/2019
Locations: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Register for Updates
Standard Versus High-Dose Trivalent Inactivated Flu Vaccine in Pediatric Acute Lymphoblastic Leukemia Patients
NCT01216332
Completed
This is a phase I safety and immunogenicity trial comparing high-dose (HD)trivalent inactivated influenza vaccine (TIV) to standard dose (SD) TIV in pediatric patients with Acute Lymphoblastic Leukemia.
Gender:
ALL
Ages:
Between 3 years and 17 years
Trial Updated:
04/29/2019
Locations: Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee
Conditions: Pediatric Patients With Acute Lymphoblastic Leukemia
Register for Updates
A Study in Healthy Adults to Assess Priming With Antigenically Mismatched Live Attenuated A/H7N3 Influenza Virus Vaccine Followed by Inactivated A/H7N9 Influenza Virus Vaccine
NCT03581903
Completed
The purpose of this study is to assess priming with antigenically mismatched live attenuated A/H7N3 influenza virus vaccine followed by inactivated A/H7N9 influenza virus vaccine in healthy adults.
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
03/22/2019
Locations: University of Rochester Medical Center Vaccine Research Unit (Outpatient), Rochester, New York
Conditions: Influenza
Register for Updates
Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine
NCT02117934
Completed
The purpose of the study is to evaluate the safety and immunogenicity of an investigational hepatitis B vaccine (HEPLISAV) in adults 18 to 70 years of age.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/18/2019
Locations: Clinical Research Advantage, Inc., Birmingham, Alabama +39 locations
Conditions: Healthy
Register for Updates
Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine
NCT01005407
Completed
The purpose of the study is to evaluate the safety, immunogenicity and lot-to-lot consistency of an investigational hepatitis B virus vaccine, HEPLISAV™, in healthy adults 40 to 70 years of age
Gender:
ALL
Ages:
Between 40 years and 70 years
Trial Updated:
03/18/2019
Locations: Not set, Huntsville, Alabama +31 locations
Conditions: Healthy
Register for Updates
Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease
NCT01282762
Completed
The purpose of this study is to determine the durability of seroprotection of HEPLISAV™ and Engerix-B® and the number of injections of each vaccine needed to maintain seroprotection in a cohort of chronic kidney disease (CKD) patients over time.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/18/2019
Locations: Clinical Research Associates of Tidewater, Norfolk, Virginia
Conditions: Chronic Kidney Disease
Register for Updates
Evaluation of a Single Vaccination of One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) and a Single Dose Level of a 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults Aged 65 to <86 Years
NCT01643941
Completed
This is a Phase 1 and Phase 2 study of a single vaccination with one of three dose levels of a 4-antigen investigational vaccine against Staphylococcus aureus (SA4Ag) and a single dose level of a 3-antigen Staphylococcus aureus vaccine (SA3Ag). The main goal of the study is to determine how safe and well tolerated the vaccine is as well as to describe the immune response elicited by the vaccine in healthy adults aged 65 to \<86 years. In addition, the study aims to assess the effect of the Staph... Read More
Gender:
ALL
Ages:
Between 65 years and 85 years
Trial Updated:
02/28/2019
Locations: Broward Research Group, Hollywood, Florida +6 locations
Conditions: Staphylococcal Infections
Register for Updates
Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years
NCT01364571
Completed
This is a first-in-human (Phase 1) and Phase 2 study of a single vaccination with one of three dose levels of an investigational vaccine against Staphylococcus aureus (SA4Ag). The main goal of the study is to determine how safe and well tolerated the vaccine is as well as to describe the immune response elicited by the vaccine in healthy adults aged 18 to \<65 years. In addition, the study aims to assess the effect of the SA4Ag vaccine on the presence of the Staphylococcus aureus on the skin and... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
02/28/2019
Locations: Broward Research Group, Hollywood, Florida +15 locations
Conditions: Staphylococcal Infections
Register for Updates
Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies
NCT02070406
Terminated
This pilot phase I trial studies the side effects of taking ipilimumab after gene-modified T cells and vaccine therapy when treating patients with advanced cancer that has spread to other areas of the body and has not responded to standard therapies. This trial also will determine the best dose of Ipilimumab to use in this combination treatment. T cells are a special type of white blood cell (immune cell) that have the ability to kill cancer cells. T cells are taken from the blood and modified i... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
02/26/2019
Locations: Jonsson Comprehensive Cancer Center, Los Angeles, California
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant
NCT01578317
Completed
Background: - Adjuvants are substances included in vaccines that stimulate the immune system and increase the body's response to the vaccine. The AS03 adjuvant is used in seasonal flu vaccines in Europe. However, it has not been fully tested in the United States. Researchers want to test the immune responses of people who receive a bird flu vaccine with or without AS03 to better understand how the adjuvant works. This information may help develop better flu vaccines. Objectives: - To compare... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
02/22/2019
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Influenza
Register for Updates
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
NCT03146403
Terminated
The main purpose of this clinical study is to see if a maintenance dose of GEN-003 reduces the number of days that subjects have a genital herpes recurrence. The second purpose of the study is to evaluate the safety and tolerability of a maintenance dose of GEN-003.
Gender:
ALL
Ages:
All
Trial Updated:
01/29/2019
Locations: University of Alabama Birmingham, Birmingham, Alabama +7 locations
Conditions: Genital Herpes, HSV-2 Infection
Register for Updates
Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03)
NCT01910519
Completed
This study will compare the different immune responses to Influenza A (H5N1) Virus Monovalent Vaccine with and without the AS03 adjuvant. The Influenza A (H5N1) Virus Monovalent Vaccine with AS03 adjuvant vaccine is approved for use for adults to protect against flu caused by the A/H5N1 "bird flu" virus in Europe but none of the vaccines to be used in the study are approved for use in the United States. The results of this study will help researchers learn about better ways to vaccinate people a... Read More
Gender:
ALL
Ages:
Between 21 years and 45 years
Trial Updated:
01/25/2019
Locations: The Hope Clinic - Emory Vaccine Center, Decatur, Georgia
Conditions: Influenza A Virus, H5N1 Subtype
Register for Updates